What are the WIPO ST.25 requirements for nucleotide and amino acid sequence disclosures in patent applications?
WIPO ST.25 requirements for nucleotide and amino acid sequence disclosures in patent applications are outlined in MPEP 2422. These requirements are largely harmonized with USPTO requirements, but there are some key differences: WIPO ST.25 requires that nucleotide sequences containing fewer than 10 specifically defined nucleotides be included in the sequence listing. WIPO ST.25 requires that…
Read MoreHow do filing requirements for sequence listings differ between national and international applications?
Filing requirements for sequence listings can vary between national US applications, foreign applications, and international applications. MPEP 2422 highlights some key differences: For international applications filed in paper, the sequence listing part must also be provided in paper. A copy of the sequence listing in ASCII plain text must be filed on read-only optical disc…
Read MoreHow are modified bases represented in nucleotide sequence listings?
According to MPEP 2422, modified bases in nucleotide sequence listings can be represented as follows: The modified base can be represented as the corresponding unmodified base in the sequence itself. The modification must be further described in numeric identifier <223> of the Feature section of the “Sequence Listing”. Specific symbols for modified bases may be…
Read MoreWhat software can be used to generate WIPO ST.25 compliant sequence listings?
The MPEP recommends using PatentIn Version 3.5.1 software for generating sequence listings that comply with WIPO ST.25 standards. According to MPEP 2422: “PatentIn Version 3.5.1 software (see MPEP § 2430) generates sequence listings that meet all of the requirements of WIPO Standard ST.25 (2009).“ This software ensures that the generated sequence listings meet both USPTO…
Read MoreWhat are the consequences of not complying with sequence listing requirements in patent applications?
Failure to comply with sequence listing requirements in patent applications can have serious consequences, as outlined in MPEP 2422: The application may be considered incomplete or defective Examination of the application may be delayed A notice to comply may be issued, requiring a response within a specified time frame Failure to respond properly may result…
Read More